ISPC iSpecimen Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1558569 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-82.0%
TTM net income YoY5.9%
TTM EPS YoY180.8%
Revenue 3-yr CAGR-61.2%
Net income 3-yr CAGR—
Margins
Gross margin-10.3%
Operating margin-1,455.3%
Net margin-1,797.3%
FCF margin—
EBITDA margin-1,364.6%
Returns
ROE-303.9%
ROA-116.1%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets58.1%
Debt / equity0.00x
Current ratio1.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.93M | $9.29M |
| Cost of revenue | $1.71M | $5.11M |
| Gross profit | $215,665 | $4.18M |
| R&D expense | — | $1.49M |
| SG&A expense | $3.47M | $6.07M |
| Operating income | -$8.98M | -$12.73M |
| Interest expense | $1,949 | $173,771 |
| Net income | -$10.49M | -$12.50M |
| EBITDA | -$7.25M | -$10.43M |
| EPS (basic) | -2.28 | -17.58 |
| EPS (diluted) | -2.28 | -17.58 |
| Weighted avg. shares (diluted) | 4.60M | 710,852 |
| Balance sheet | ||
| Cash & equivalents | $6.88M | $1.88M |
| Receivables | $48,298 | $1.44M |
| Inventory | — | $45,110 |
| Current assets | $6.95M | $3.59M |
| PP&E, net | $25,543 | $93,563 |
| Total assets | $9.53M | $9.35M |
| Current liabilities | $6.23M | $5.77M |
| Total liabilities | $6.44M | $6.04M |
| Shareholders' equity | $3.09M | $3.31M |
| Shares outstanding | 211,976 | 1.70M |
| Cash flow statement | ||
| Operating cash flow | -$4.24M | -$8.26M |
| Capital expenditure | $454 | $31,546 |
| Free cash flow | -$4.24M | -$8.30M |
| Investing cash flow | -$1.00M | $1.98M |
| Financing cash flow | $10.24M | $5.82M |
| Depreciation & amortization | $1.73M | $2.29M |
| Stock-based compensation | $21,266 | $249,675 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.